Myrtelle Announces Presentation at the 5 th Annual Gene Therapy for Neurological Disorders Summit: Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options For Neurological Disorder Patients
Wakefield, Mass., November 7, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
November 6, 2023
This article is featured on another website.
Go to article
November 30, 2023
Exciting Update! Explore Myrtelle’s Insightful Slide Presentation on Gene Therapy for Canavan Disease Preliminary One-Year Results from Meeting on the Mesa.
Here is the link to Alliance for Regenerative Medicine's Youtube Channel. Mark Hurtt gave a presentation last month at Mesa, here is the slideshow he presented with…
November 30, 2023
Exciting Update! Explore Myrtelle’s Insightful Slide Presentation on Gene Therapy for Canavan Disease Preliminary One-Year Results from Meeting on the Mesa.
Here is the link to Alliance for Regenerative Medicine's Youtube Channel. Mark Hurtt gave a presentation last month at Mesa, here is the slideshow he presented with…
October 13, 2023
Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata
October 13, 2023